Rhenman & Partners Asset Management AB Buys 7,000 Shares of IQVIA Holdings Inc. $IQV

Rhenman & Partners Asset Management AB grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 35.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,500 shares of the medical research company’s stock after purchasing an additional 7,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in IQVIA were worth $5,973,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of IQV. Brighton Jones LLC lifted its holdings in shares of IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of IQVIA in the second quarter valued at approximately $514,000. First Trust Advisors LP lifted its holdings in shares of IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after purchasing an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after acquiring an additional 1,155 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Truist Financial dropped their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Evercore reiterated an “outperform” rating and set a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Royal Bank Of Canada assumed coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $174.00 to $213.00 in a report on Monday, March 9th. Finally, Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, IQVIA has a consensus rating of “Buy” and an average price target of $224.13.

IQVIA Stock Performance

Shares of IQV opened at $181.10 on Friday. The firm has a market cap of $30.23 billion, a PE ratio of 22.44, a PEG ratio of 1.55 and a beta of 1.21. The stock’s fifty day moving average price is $173.56 and its two-hundred day moving average price is $193.68. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 1 year low of $153.01 and a 1 year high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its Board of Directors has initiated a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.